Spectral Med Inc
🇨🇦XTSE.EDTCanadaHealthcare
PriceCA$1.16+0.02 (+1.75%)
Latest anomalies
Very negative 3 detected in the last 120 days
- High: 3
- Medium: 4
- Low: 0
Volume: a spike above the 20-day average
Daily return: an extreme move down, far outside its trailing 60-day range
12-1M momentum: flipped sign, from positive to negative
Free cash flow to debt: a sudden drop below its trailing quarter average
Long-term debt to equity: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Diagnostics & Research
- Canada
Identity
- Exchange
- Toronto Stock Exchange . XTSE
- Type
- Stock
- ISIN
- CA8475771033
- CUSIP
- 847577103
Company
- Employees
- 29
- Headquarters
- Toronto, Canada
- Website
- https://spectraldx.com
Market
- Shares outstanding
- 293.6M
- Market cap
- CA$335.4M
Highlights
- Market cap
- CA$335.4M
- EPS LTM
- -CA$0.07calculatedCalculated by Finzer, not reported by the data provider.
- P/E LTM
- -15.93calculatedCalculated by Finzer, not reported by the data provider.
- Div yield
- 0%
Fundamentals (LTM)
- Revenue
- CA$2.53M+33.19%up year on year
- Net income
- -CA$21.38M-15.51%down year on year
- Gross margin
- 54.23%+158.34%up year on year
- Free cash flow
- -CA$9.52M-9.26%down year on year
Latest news
News is not sourced for this exchange.
Business summary
Spectral Med Inc is a company in the healthcare sector, listed on Toronto Stock Exchange (Canada) under the ticker EDT. Its market capitalisation is CA$335.4M, from 293.6M shares outstanding, as of . Across the 250 trading sessions to the shares traded between CA$1.03 and CA$1.65, and the last close of CA$1.16 sits 21% of the way up that range. The company is headquartered in Toronto, Canada, and employs about 29 people.
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.